Launch of plasma kallikrein inhibitor "Orideo Capsules" for hereditary angioedema attack suppression (manufactured and marketed by Ophan Pacific Corporation)
Reorganization of market classification and transition from the First Section of the Tokyo Stock Exchange to the Prime Market
Reorganization of market classification and transition from the First Section of the Tokyo Stock Exchange to the Prime Market
Launch of atopic dermatitis treatment and psoriasis treatment "Vitamark Cream"
Launch of atopic dermatitis treatment and psoriasis treatment "Vitamark Cream" (manufactured and marketed by JT)
Becoming a wholly owned subsidiary of Shionogi & Co., Ltd.
Launch of viral warts treatment "Wycans External Liquid"
VTAMA Cream Approved for Pediatric Atopic Dermatitis
Shionogi & Co., Ltd. and Torii Pharmaceutical Co., Ltd. obtained domestic marketing approval for VTAMA® Cream 0.5% for the indication of pediatric atopic dermatitis in children under 12 years of age. The approval was based on the results of a domestic Phase III trial in children aged 2 to under 12. The product demonstrated superiority over the vehicle cream on the primary endpoint, and its safety during long-term administration was also reported to be favorable.
Torii Pharmaceutical Announces Approval Transfer and Sales Transfer of External Corticosteroid Drugs
Torii Pharmaceutical announced that it will transfer the manufacturing and sales approval of the external corticosteroid drugs "Locoid® Ointment 0.1%" and "Locoid® Cream 0.1%" on December 1, 2026, and transfer sales and distribution to Cheplapharm on January 5, 2027. These products are effective for skin conditions such as eczema and dermatitis.
TO-208 Phase III Trial for Common Warts Begins in Japan
Tori Pharmaceutical announced that the first subject enrollment and initial dosing have been completed for the domestic Phase III clinical trial of TO-208, a viral wart treatment containing cantharidin as the active ingredient, targeting common warts. The trial is being conducted in the United States and Japan for patients aged two years and older with common warts.
Positive interim analysis results in Tapinarof infant AD trial
Shionogi Pharmaceutical and Torii Pharmaceutical announced favorable interim analysis results in a domestic Phase III trial of 0.5% tapinarof cream for infant atopic dermatitis patients. In a trial where patients aged 3 months to under 24 months were treated for 52 weeks, improvement in dermatitis was demonstrated and safety was confirmed. Based on the trial results, the two companies aim to expand the indication for infant patients in Japan.
Signed an absorption merger agreement with Shionogi Pharmaceutical
Toriuchi Pharmaceutical signed an absorption merger agreement on April 27, 2026, with Shionogi Pharmaceutical as the surviving company and Toriuchi Pharmaceutical as the extinct company. The effective date is April 1, 2027. The two companies say that the merger will strengthen their pharmaceutical information provision activities and accelerate efforts to deliver their flagship products to more patients.
Notice of Personnel Changes at Torii Pharmaceutical (Effective April 1, 2026)
Torii Pharmaceutical will carry out personnel changes effective April 1, 2026, and will reassign its executives.
Collectim lotion, domestic approval application
Shionogi Pharmaceutical and Torii Pharmaceutical have applied for domestic manufacturing and sales approval for the 0.5% lotion formulation of the atopic dermatitis treatment drug "Collectim". The application is based on favorable results from Phase 1 skin safety studies and Phase 3 bioequivalence studies.
Support for the basic policy of absorption merger with Shionogi Pharmaceutical
Shionogi Pharmaceutical has decided to implement an absorption merger with Torii Pharmaceutical, effective April 1, 2027, with Shionogi as the surviving company and Torii as the absorbed company. Torii Pharmaceutical also resolved in its board of directors to support this basic policy. Through the merger, the two companies aim to accelerate initiatives such as strengthening the provision of pharmaceutical information and contributing to healthcare.
New Release of Wicancs 0.71% External Liquid
Torii Pharmaceutical announced on February 9, 2026 the launch of the topical agent containing cantharidin, 'Wicancs® External Liquid 0.71%', indicated for infectious soft tissue tumors. In the domestic Phase III clinical trial, superiority over placebo was confirmed in the primary endpoint, and no particular safety or tolerability issues were observed. The company expects it to become a new treatment option.
Relocation of Headquarters Sales Functions and Southern Metropolitan Area Branch
Torii Pharmaceutical will relocate its headquarters sales functions (pharmaceutical sales group) and the Southern Metropolitan Area branch. The sales start date is December 15, 2025, and the new address is 29th floor, Sumitomo Real Estate Tokyo Mita South Tower, 5-27-3 Mita, Minato-ku, Tokyo.
